BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: Long-term follow-up of the Dutch MRISC screening study

Journal of Clinical Oncology

Volumn 28, Issue 36, 2010, Pages 5265-5273

  Rijnsburger, Adriana J ^a   Obdeijn, Inge Marie ^a   Kaas, Reinoutje ^a   Tilanus Linthorst, Madeleine M A ^a   Boetes, Carla ^a   Loo, Claudette E ^a   Wasser, Martin N J M ^a   Bergers, Elisabeth ^a   Kok, Theo ^a   Muller, Sara H ^a   Peterse, Hans ^a   Tollenaar, Rob A E M ^a   Hoogerbrugge, Nicoline ^a   Meijer, Sybren ^a   Bartels, Carina C M ^a   Seynaeve, Caroline ^a   Hooning, Maartje J ^a   Kriege, Mieke ^a   Schmitz, Paul I M ^a   Oosterwijk, Jan C ^a   De Koning, Harry J ^a   Rutgers, Emiel J T ^a   Klijn, Jan G M ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST EXAMINATION; CANCER DIAGNOSIS; CANCER INVASION; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CLINICAL EXAMINATION; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; EARLY DIAGNOSIS; FAMILIAL CANCER; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC ASSOCIATION; HETEROZYGOTE; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MAMMOGRAPHY; METASTASIS; NETHERLANDS; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MAGNETIC RESONANCE IMAGING; MAMMOGRAPHY; MASS SCREENING; MIDDLE AGED; MUTATION; PHYSICAL EXAMINATION; PROSPECTIVE STUDIES;

EID: 79951860891     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.27.2294     Document Type: Article

References (49)

1. Antoniou A, Pharoah PD, Narod S, et al: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet 72:1117-1130, 2003 (Pubitemid 36530000)
2. King MC, Marks JH, Mandell JB: Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302:643-646, 2003 (Pubitemid 37310920)
3. Ford D, Easton DF, Stratton M, et al: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families: The Breast Cancer Linkage Consortium. Am J Hum Genet 62:676-689, 1998 (Pubitemid 28164626)
4. Claus EB, Risch N, Thompson WD: Autosomal dominant inheritance of early-onset breast cancer: Implications for risk prediction. Cancer 73:643-651, 1994 (Pubitemid 24046606)
5. Meijers-Heijboer H, van Geel B, van Putten WL, et al: Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 345:159-164, 2001 (Pubitemid 32662123)
6. Rebbeck TR, Kauff ND, Domchek SM: Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 101:80-87, 2009
7. Cuzick J, Powles T, Veronesi U, et al: Overview of the main outcomes in breast-cancer prevention trials. Lancet 361:296-300, 2003 (Pubitemid 36126189)
8. Robson M, Offit K: Clinical practice: Management of an inherited predisposition to breast cancer. N Engl J Med 357:154-162, 2007 (Pubitemid 47057733)
9. Metcalfe KA, Birenbaum-Carmeli D, Lubinski J, et al: International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer 122:2017-2022, 2008 (Pubitemid 351441190)
10. Kriege M, Brekelmans CT, Boetes C, et al: Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 351:427-437, 2004
11. Warner E, Plewes DB, Hill KA, et al: Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 292:1317-1325, 2004 (Pubitemid 39223222)
12. Leach MO, Boggis CR, Dixon AK, et al: Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: A prospective multicentre cohort study (MARIBS). Lancet 365:1769-1778, 2005 (Pubitemid 40744657)
13. Kuhl CK, Schrading S, Leutner CC, et al: Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 23:8469-8476, 2005
14. Hagen AI, Kvistad KA, Maehle L, et al: Sensitivity of MRI versus conventional screening in the diagnosis of BRCA-associated breast cancer in a national prospective series. Breast 16:367-374, 2007 (Pubitemid 47157808)
15. Weinstein SP, Localio AR, Conant EF, et al: Multimodality screening of high-risk women: A prospective cohort study. J Clin Oncol 27:6124-6128, 2009
16. Kuhl C, Weigel S, Schrading S, et al: Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: The EVA trial. J Clin Oncol 28:1450-1457, 2010
17. Warner E, Messersmith H, Causer P, et al: Systematic review: Using magnetic resonance imaging to screen women at high risk for breast cancer. Ann Intern Med 148:671-679, 2008 (Pubitemid 351669112)
18. Kriege M, Klijn JGM: Efficacy of MRI and mammography for breast cancer screening in women with genetic predisposition, American Society of Clinical Oncology, 2007 Educational Book. Alexandria, VA, American Society of Clinical Oncology, pp 135-141, 2007
19. Sardanelli F, Podo F: Breast MR imaging in women at high-risk of breast cancer. Is something changing in early breast cancer detection? Eur Radiol 17:873-887, 2007
20. Leach MO: Breast cancer screening in women at high risk using MRI. NMR Biomed 22:17-27, 2009
21. Klijn JG: Early diagnosis of hereditary breast cancer by magnetic resonance imaging: What is realistic? J Clin Oncol 28:1441-1445, 2010
22. Saslow D, Boetes C, Burke W, et al: American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57:75-89, 2007 (Pubitemid 46535708)
23. National Institute for Health and Clinical Excellence: Familial breast cancer. The classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care. Update, July 2006. Available at: Http://www.nice.org.uk.
24. Nationaal Borstkanker Overleg Nederland: Richtlijn mammacarcinoom 2008. Available at: Http://www.cbo.nl.
25. Kriege M, Brekelmans CTM, Boetes C, et al: MRI screening for breast cancer in women with familial or genetic predisposition: Design of the Dutch National Study (MRISC). Fam Cancer 1:163-168, 2001
26. Illustrated Breast Imaging Reporting and Data System (BI-RADS) (ed 3rd). Reston, VA, American College of Radiology, 1998
27. Liberman L, Menell JH: Breast imaging reporting and data system (BI-RADS). Radiol Clin North Am 40:409-430, 2002 (Pubitemid 34765031)
28. Obdeijn IM, Loo CE, Rijnsburger AJ, et al: Assessment of false-negative cases of breast MR imaging in women with a familial or genetic predisposition. Breast Cancer Res Treat 119:399-407, 2010
29. Rijnsburger AJ: Effects and costs of breast cancer screening in women with a familial or genetic predisposition (thesis). Rotterdam, the Netherlands, 2005
30. Gilbert FJ, Warren RM, Kwan-Lim G, et al: Cancers in BRCA1 and BRCA2 carriers and in women at high risk for breast cancer: MR imaging and mammographic features. Radiology 252:358-368, 2009
31. Kuhl CK, Schrading S, Bieling HB, et al: MRI for diagnosis of pure ductal carcinoma in situ: A prospective observational study. Lancet 370:485-492, 2007 (Pubitemid 47214635)
32. Plevritis SK, Kurian AW, Sigal BM, et al: Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. JAMA 295:2374-2384, 2006 (Pubitemid 43788105)
33. Griebsch I, Brown J, Boggis C, et al: Costeffectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer. Br J Cancer 95:801-810, 2006 (Pubitemid 44498093)
34. Norman RP, Evans DG, Easton DF, et al: The cost-utility of magnetic resonance imaging for breast cancer in BRCA1 mutation carriers aged 30-49. Eur J Health Econ 8:137-144, 2007 (Pubitemid 46742897)
35. Kaas R, Kroger R, Peterse JL, et al: The correlation of mammographic-and histologic patterns of breast cancers in BRCA1 gene mutation carriers, compared to age-matched sporadic controls. Eur Radiol 16:2842-2848, 2006 (Pubitemid 44823938)
36. Tilanus-Linthorst M, Verhoog L, Obdeijn IM, et al: A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography. Int J Cancer 102:91-95, 2002
37. Tilanus-Linthorst MMA, Kriege M, Boetes C, et al: Hereditary breast cancer growth rates and its impact on screening policy. Eur J Cancer 41:1610-1617, 2005 (Pubitemid 40981844)
38. Tilanus-Linthorst MMA, Obdeijn I-M, Hop WCJ, et al: BRCA1 mutation and young age predict fast breast cancer growth in the Dutch, United Kingdom, and Canadian magnetic resonance imaging screening trials. Clin Cancer Res 13:7357-7362, 2007
39. Lakhani SR, Jacquemier J, Sloane JP, et al: Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 90:1138-1145, 1998 (Pubitemid 28380718)
40. Brekelmans CT, Tilanus-Linthorst MM, Seynaeve C, et al: Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases. Eur J Cancer 43:867-876, 2007 (Pubitemid 46366688)
41. Moller P, Evans DG, Reis MM, et al: Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status. Int J Cancer 121:1017-1020, 2007 (Pubitemid 47101637)
42. Lakhani SR, Reis-Filho JS, Fulford L, et al: Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 11:5175-5180, 2005 (Pubitemid 41003703)
43. Verhoog LC, Brekelmans CT, Seynaeve C, et al: Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 351:316-321, 1998 (Pubitemid 28052696)
44. Brekelmans CT, Seynaeve C, Menke-Pluymers M, et al: Survival and prognostic factors in BRCA1-associated breast cancer. Ann Oncol 17:391-400, 2006 (Pubitemid 43329574)
45. Otto SJ, Fracheboud J, Looman CW, et al: Initiation of population-based mammography screening in Dutch municipalities and effect on breast-cancer mortality: A systematic review. Lancet 361:1411-1417, 2003 (Pubitemid 36515040)
46. Chappuis PO, Rosenblatt J, Foulkes WD: The influence of familial and hereditary factors on the prognosis of breast cancer. Ann Oncol 10:1163-1170, 1999 (Pubitemid 29533564)
47. Bonadona V, Dussart-Moser S, Voirin N, et al: Prognosis of early-onset breast cancer based on BRCA1/2 mutation status in a French population-based cohort and review. Breast Cancer Res Treat 101:233-245, 2007 (Pubitemid 46115430)
48. Kriege M, Seynaeve C, Meijers-Heijboer H, et al: Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 27:3764-3771, 2009
49. Byrski T, Gronwald J, Huzarski T, et al: Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 28:375-379, 2010